Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- SBI Biotech Licenses Autoimmune Disease Med to Kyowa Kirin
January 13, 2017
- Takeda Invests US$125 Million in Maverick for T-Cell Therapy, Buyout Eyed
January 13, 2017
- AbbVie’s 8-Week Hep C Med Delivers High SVR12 Rate in Japanese
January 13, 2017
- Imigran AG to Get Off Strong Start: Aspen Japan
January 12, 2017
- Astellas Bows Out from Flu Vaccine Development Pact with UMN
January 11, 2017
- Daiichi Sankyo to Shutter Indian Research Subsidiary
January 11, 2017
- Plavix AG Now Has All Same Indications as Originator
January 11, 2017
- Daiichi Sankyo Gets Japan Rights to Kite’s CAR T-Cell Therapy
January 11, 2017
- Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
- Teva Takeda Recalls Ciprofloxacin Generic
January 11, 2017
- Janssen, Fukushima Medical Univ. to Engage in Joint Research for ADHD Biomarkers
January 11, 2017
- Pharma Leaders Urge Govt to Lend Ear to Industry Opinions for Pricing Revamp
January 10, 2017
- Otsuka Files Schizophrenia Med Brexpiprazole in Japan
January 10, 2017
- Takeda, US Biotech Strike Deal on Celiac Disease Treatment
January 10, 2017
- Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status
January 10, 2017
- Takeda to Buy US Oncology Firm Ariad
January 10, 2017
- Eisai Expands Deal with Arena, Gets All Global Rights to Belviq
January 6, 2017
- Kyowa Kirin’s KRN23 Filed in Europe for X-Linked Hypophosphatemia
January 6, 2017
- SSP Now under Sanofi Group in Japan after BI Biz Swap
January 6, 2017
- ASKA Eyes 33% Rise in Women’s Health Sales by FY2020
January 5, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…